Clinical Trials Browser

Has results × Central Nervous System Neoplasms × Irinotecan × Clear all

NCT02975882 2025-01-14

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 1 Completed

33 enrolled 15 charts

Central Nervous System Neoplasms

NCT03323034 2024-10-22

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Phase 1 Completed

30 enrolled 19 charts

Lymphoma, Central Nervous System Neoplasms

NCT02095132 2023-09-26

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 1/2 Completed

76 enrolled 25 charts

Medulloblastoma, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive

NCT00876993 2023-07-03

Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors

Phase 1 Completed

26 enrolled 16 charts

Central Nervous System Neoplasms

NCT01217437 2021-07-23

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Phase 2 Completed

108 enrolled 14 charts

Medulloblastoma, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive